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A B S T R A C T
BK polyomavirus (BKPyV) is a ubiquitous pathogen in the human population that is asymptomatic in healthy
individuals, but can be life-threatening in those undergoing kidney transplant. To-date, no vaccines or anti-viral
therapies are available to treat human BKPyV infections. New therapeutic strategies are urgently required. In this
study, using a rational pharmacological screening regimen of known ion channel modulating compounds, we
show that BKPyV requires cystic fibrosis transmembrane conductance regulator (CFTR) activity to infect primary
renal proximal tubular epithelial cells. Disrupting CFTR function through treatment with the clinically available
drug glibenclamide, the CFTR inhibitor CFTR172, or CFTR-silencing, all reduced BKPyV infection. Specifically,
time of addition assays and the assessment of the exposure of VP2/VP3 minor capsid proteins indicated a role for
CFTR during BKPyV transport to the endoplasmic reticulum, an essential step during the early stages of BKPyV
infection. We thus establish CFTR as an important host-factor in the BKPyV life cycle and reveal CFTR mod-
ulators as potential anti-BKPyV therapies.
1. Introduction
BK polyomavirus (BKPyV) was first isolated in 1971 and is a sig-
nificant risk factor for renal transplant dysfunction and allograft loss
(Chong et al., 2019). BKPyV was identified at a similar time to the re-
lated JC polyomavirus (JCPyV) (Gardner et al., 1971), which remained
the only human polyomaviruses identified until 2007. To date, 13
human polyomaviruses have been discovered (Moens et al., 2017) with
interest in this virus family remerging due to their increasing associa-
tion with human disease (DeCaprio and Garcea, 2013; Stakaityte et al.,
2014; Helle et al., 2017).
BKPyV establishes a life-long persistent infection of the urinary tract
and kidneys in> 80% of adults (Kean et al., 2009; Chesters et al.,
1983). BKPyV causes a sub-clinical infection in healthy individuals, but
a number of diseases are associated with uncontrolled virus replication
in the immunosuppressed. Polyomavirus-associated haemorrhagic cy-
stitis (PVHC) afflicts 10–25% of bone marrow transplant recipients and
polyomavirus-associated nephropathy (PVAN) occurs in up to 10% of
kidney transplant patients, leading to the lytic destruction of tubular
epithelial cells and a loss of graft function in up to 80% of cases (Helle
et al., 2017; Ahsan and Shah, 2006). The treatment of BKPyV-associated
disease is limited to immune suppression medication to allow the host
immune response to fight the infection, coupled to use of broad-spec-
trum nucleoside analogues. However, the reduction of im-
munosuppression enhances the risk of host graft rejection whilst anti-
viral nucleoside analogues display questionable efficacy and known
nephrotoxicity (Kuypers, 2012). JCPyV can, on rare occasions also
cause PVAN. A clear and unmet need to study this family of viruses and
identify potent and direct anti-viral therapeutics therefore exists.
BKPyV consists of a capsid containing a ~5 kb circular double-
stranded DNA genome (Bennett et al., 2012). The genome is composed
of two highly conserved regions that code for early and late viral pro-
teins, separated by a non-coding control region containing the origin of
DNA replication and promoter region. The early region encodes the
large and small tumour antigens, necessary for regulating virus tran-
scription and replication. The late region encodes the major capsid
protein VP1 and the minor capsid proteins VP2 and VP3 (Helle et al.,
2017). BKPyV virions consist of 360 copies of VP1 that form 72
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pentamers arranged in an icosahedral capsid (Hurdiss et al., 2016).
Each VP1 monomer interacts with a neighbouring monomer through a
C-terminal extending arm, and through hydrophobic interactions with
internal VP2 and VP3 molecules (Hurdiss et al., 2016, 2018). Within the
late region, BKPyV also encodes a small hydrophobic auxiliary protein
termed the agnoprotein, which is essential for virus release from in-
fected cells (Gerits and Moens, 2012; Panou et al., 2018).
BKPyV infects the epithelial lining of the collective ducts, the
transitional epithelial cells of the renal calyces, the parietal epithelium
of the Bowman's capsule, and the transitional epithelium of the renal
pelvis and urinary tract (Meehan et al., 2006). The major function of
these epithelial tissues is to maintain ion, solute, and water homeostasis
through a concerted effort of ion transporters that control sodium
(Na+) and potassium (K+) reabsorption, K+ efflux, and chloride (Cl−)
secretion (Palmer and Sackin, 1988). At the cellular level, ion channels
regulate many important physiological functions including cell volume,
apoptosis, and the ionic homeostasis of intracellular vesicles/organelles
(Bardou et al., 2009; Roger et al., 2015; O'Grady and Lee, 2003). These
cellular functions frequently overlap with those hijacked during virus
infection. Accordingly, the pharmacological modulation of host cell ion
channel activity can impede an array of important human viruses in-
cluding Ebola virus, hepatitis C virus and bunyaviruses (Charlton et al.,
2019; Hover et al., 2017, 2018; Igloi et al., 2015; Sakurai et al., 2015).
However, a requirement for ionic homeostasis and its contribution to
the ability of BKPyV to persistently infect cells has not been explored.
In this study, using an established panel of ion channel modulating
drugs, we assessed the contribution of cellular ion channel activity to
the BKPyV lifecycle. We demonstrate that pharmacological blockers of
the cystic fibrosis transmembrane conductance regulator (CFTR) im-
pede BKPyV infection in primary kidney cells. One of these blockers,
glibenclamide, is a clinically approved anti-diabetic drug, thus re-
vealing a potent FDA approved anti-BKPyV therapeutic. We finally
show that the CFTR blockers inhibit the early stages of BKPyV infection
following virus penetration into cells. This furthers our understanding
of BKPyV infection and replication strategies and reveals new and ex-
citing strategies for much needed anti-BKPyV therapeutics.
2. Results
2.1. Glibenclamide inhibits BKPyV infection
Ion channels have emerged as essential host factors in the lifecycles
of a number of important human viruses (Hover et al., 2017). To de-
termine if the activity of kidney-expressed channels are required during
the BKPyV lifecycle, BKPyV infection assays were performed in the
presence of well-characterised modulators of renal K+ channels. We
initially selected K+ channels as they represent the largest ion channel
family (over 70 different K+ channel genes per cell) for which an array
of blockers are available (Hover et al., 2017). Assays were performed in
primary renal proximal tubular epithelial (RPTE) cells, used as a phy-
siologically relevant cell culture infection model that maintains the
apical and basolateral membrane domains critical for ion transport
(Low et al., 2004). BKPyV infection was measured through the ex-
pression of the VP1 major capsid protein; known to correlate with virus
production (Panou et al., 2018; Low et al., 2004). Drugs at pharmaco-
logically relevant concentrations were added to cells with virus super-
natants, permitting the inhibition of all lifecycle stages. Data from these
assays revealed that inhibitors of voltage gated K+ channels (4-ami-
nopyridine, 4-AP), calcium-activated K+ channels (Apamin), inwardly
rectifying K+ channels (BaCl2), two-pore K+ channels (quinidine) and
the renal outer medullary K+ channel (ROMK, VU591) did not influ-
ence BKPyV infection, whilst the KATP channel inhibitor glibenclamide
produced ≥ 80% inhibition of BKPyV infection (Fig. 1A).
To further explore the inhibitory effects of glibenclamide, infection
assays were performed at a range of glibenclamide concentrations
(0–20 μM). We observed a concentration-dependent decrease in VP1
levels (Fig. 1B, open bars) with a negligible impact on RPTE cell viability
(≥80% at all concentrations assessed; Fig. 1B, grey bars). The inhibition
of BKPyV occurred irrespective of the multiplicity of infection of
BKPyV, as a similar impairment was observed at an MOI of 0.5 and 5
(≥80% decrease; p≤ 0.0001) in the presence of 20 μM glibenclamide
(Fig. 1C). Glibenclamide also inhibited the expression of the minor
capsid protein VP3, confirming that the effects were not restricted to
VP1 (Fig. 1D). Glibenclamide also reduced viral genome production as
confirmed through qPCR analysis of BKPyV genome copy number
(≥80% decrease; p ≤ 0.005 Fig. 1E). The levels of inhibition were
comparable to cidofovir; a known inhibitor of BKPyV replication
(Fig. 1E) (Safrin et al., 1997). We further assessed the impact of glib-
enclamide and cidofovir treatment on the production of infectious
BKPyV progeny by infecting naïve RPTE cells with the media from virus
infected control and inhibitor treated cells, followed by staining for the
production of the VP1 capsid protein. Consistent with these findings,
we observed a ≥80% (p ≤ 0.0001) loss of infectious virus production
in cells treated with either glibenclamide or cidofovir (Fig. 1Fi-ii). The
EC50 of glibenclamide inhibition against BKPyV was found to be
5.454 μM (Fig. 1G). Taken together, these data identified a requirement
for glibenclamide sensitive channels during the BKPyV lifecycle in
primary RPTE cells.
2.2. KATP channels are not required for BKPyV infection
Glibenclamide is commonly used to treat type II neonatal diabetes
through the pharmacological blockade of KATP channels (Bhattia et al.,
1970; Mikhailov et al., 2001; Gudat et al., 1998). The closure of KATP
channels results in a loss of K+ efflux and membrane depolarization
(Nichols and Lederer, 1991; Nichols et al., 1991; Aguilar-Bryan et al.,
1992; Niki et al., 1989). KATP channels are composed of an inwardly
rectifying potassium channel KIR (KIR6.1, KIR6.2) and a sulphonylurea
sub-unit (SUR1, SUR2A and SUR2B) which regulate the activity of KIR
through their sensitivity to the ATP/ADP ratio and other metabolites
(Larsson et al., 1993; Hilgemann and Ball, 1996; Challinor-Rogers and
McPherson, 1994; Glukhov et al., 2013; Ruknudin et al., 1998). Spe-
cifically, glibenclamide binds to SUR1 to inhibit KATP channel activity
(Mikhailov et al., 2001). Whilst the potent anti-BKPyV activity of
glibenclamide implicates this channel family as required during BKPyV
infection, the insensitivity of BKPyV to BaCl2 questions KATP involve-
ment, since BaCl2 is a known inhibitor of KIR subunits (Wellman et al.,
1996; Teramoto et al., 2006; Lippiat et al., 2002). We therefore in-
vestigated in further detail if KATP channels are the cellular target in-
fluencing BKPyV infection.
Firstly, we assessed other characterised KATP blocking drugs for
their effects on BKPyV. Tolbutamide, a high-affinity KATP channel
blocker; guanidine; 4-morpholinecarboximidine-N-1-adamantyl-N′-cy-
clohexyl hydrochloride (U-37883A), a sub-micromolar KATP blocker;
and 5-hydroxydecanoate (5-HD), a mitochondria KATP channel specific
inhibitor were investigated at concentrations known to inhibit KATP
function (Katsumata and Katsumata, 1990; Bijlstra et al., 1996;
Meisheri et al., 1993; Teramoto, 2006; Nakagawa et al., 2005; Sarre
et al., 2005). Analysis of the percentage of BKPyV infected cells re-
vealed a modest but significant reduction in BKPyV infection in the
presence of tolbutamide, whilst no effects of U-37883A or 5-HD on
BKPyV were observed (glibenclamide≥80% decrease; p < 0.0005 vs.
tolbutamide 20% decrease, p < 0.05) (Fig. 2A). These data suggested
that other KATP channel inhibitors fail to recapitulate the inhibition by
glibenclamide.
We further investigated the involvement of KATP channels by si-
lencing the expression of SUR1, SUR2A and SUR2B in RPTE cells prior
to BKPyV infection (Fig. 2B). qRT‐PCR data demonstrated no loss of
VP1 expression, and thus BKPyV infection in the face of successful
ABCC8 (SUR1), ABCC9A (SUR2A) and ABCC9B (SUR2B) silencing
(Fig. 2B). Taken together, these data strongly suggest that the inhibitory
effects of glibenclamide on BKPyV infection are independent of KATP
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2.3. CFTR is required during BKPyV infection
In addition to KATP channels, glibenclamide is a known blocker of
the cystic fibrosis transmembrane conductance regulator (CFTR)
(Sheppard and Welsh, 1992; Sheppard and Robinson, 1997). CFTR is an
ABC transporter that is also a Cl− permeable channel expressed in all
nephron segments and the principal cells of the cortical and medullary
collecting ducts (Souza-Menezes and Morales, 2009). A potential role
for CFTR in BKPyV infection was first investigated through CFTR siRNA
silencing experiments. The transfection of RPTE cells with CFTR
(caption on next page)
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specific siRNA yielded a ~75% knockdown in CFTR mRNA expression
(p ≤ 0.0001), which resulted in a ~25% decrease in VP1 expression
(p ≤ 0.0001) compared to scrambled siRNA controls (Fig. 3A). Upon
infection with BKPyV, we also observed a ~25% (p≤ 0.0003) increase
in the levels of CFTR mRNA expression, suggesting that the virus may
up-regulate CFTR expression. A challenge with these experiments was
that the biochemical half-life of CFTR exceeds 48 h compared to the
~25.5 h reported for SUR1, SUR2A and SUR2B. We therefore reasoned
that a pharmacological approach to CFTR inhibition was more suitable.
To achieve this, BKPyV infections were performed in the presence of the
CFTR specific inhibitor CFTR172 (Caci et al., 2008). In these assays,
concentrations of CFTR172 as low as 10 μM significantly inhibited VP1
expression (Fig. 3B) (≥80% decrease at 10 μm; p≤ 0.0001, open bars),
with minimal impact on RPTE cell viability (Fig. 3B, grey bars). As
observed with glibenclamide, the inhibition of BKPyV occurred at MOIs
of 0.5 and 5 and so was independent of BKPyV MOI (Fig. 3C ≥ 80%
decrease; p ≤ 0.005) and reduced VP1 and VP3 protein expression
(Fig. 3D). BKPyV genome copy numbers were also reduced upon
treatment with CFTR172 to levels comparable to cidofovir (Fig. 3E 80%
decrease; p < 0.005), which correlated with a significant impairment
in virus replication, as judged by VP1 and VP3 protein expression
(Fig. 3D). Importantly, CFTR172 treatment also reduced the production
of infectious progeny virus from RPTE cells (Fig. 3Fi-ii, CFTR172≥80%
decrease; p ≤ 0.0005, cidofovir ≥90% decrease; p ≤ 0.0001). The
EC50 of CFTR against BKPyV was 5.24 μM (Fig. 3G). The combination of
our CFTR172, glibenclamide and CFTR depletion experiments therefore
support a role for kidneyexpressed CFTR as an important host factor
during BKPyV infection.
2.4. CFTR is required during the early stages of BKPyV infection
The stage of the BKPyV lifecycle that requires CFTR activity was
next investigated through time-of-addition experiments using glib-
enclamide and CFTR172. Here, cells were infected for 60 min and drugs
were added at defined time points post-infection (hpi). When drugs
were added 10 hpi, VP1 expression was largely unaffected, suggesting
that neither glibenclamide nor CFTR172 affect BKPyV once virus in-
fection has been established (Fig. 4A–B). To further define the temporal
window during which CFTR inhibition acts to impair BKPyV, RPTE cells
were treated with inhibitor compounds at intervals between 1 and 10
hpi. Maximal impairment of BKPyV infection by CFTR inhibition was
achieved within 4 hpi, and the levels of inhibition gradually decreased
when drugs were added at later times (Fig. 4A–B). Taken together,
these data demonstrate that BKPyV infection is primarily restricted by
synchronous or early treatment with CFTR blockers (≤4 hpi) as op-
posed to when virus gene expression has been initiated (≥10 hpi).
The kinetics of inhibition indicated that CFTR may be required prior
to delivery of BKPyV virions into the endoplasmic reticulum (ER),
which typically occurs between 6 and 12 hpi (Jiang et al., 2009). To
determine if glibenclamide or CFTR172 treatment impaired BKPyV ER-
Fig. 1. K+ channel inhibition impairs BKPyV infection. A) BKPyV infected RPTE cells were treated with 4-AP (0.5 mM), apamin (0.5 μM), BaCl2 (1 mM),
glibenclamide (20 μM), quinidine (50 μM), TEA (20 mM) and VU591 (10 μM) for 48 h. Cells were fixed and probed with anti-VP1 and anti-mouse Alexa-fluor 488
secondary antibodies. The percentage of BKPyV infected cells was quantified using IncuCyte ZOOM software and normalised to untreated cells. B) BKPyV infected
RPTE cells were treated with increasing concentrations (0–20 μM) of glibenclamide. At 48 hpi, cells were fixed and stained for BKPyV VP1. The percentage of BKPyV
infected cells was normalised to untreated cells (open bars). Cell viability was assessed by MTT assays. Values were normalised to untreated controls (grey bars). C)
RPTE cells were infected with BKPyV at MOI 0.5 or 5 and treated with 20 μM glibenclamide. The percentage of BKPyV infected cells was quantified using IncuCyte
ZOOM software and normalised to untreated cells. D) Lysates from BKPyV infected RPTE cells treated with glibenclamide (20 μM) were resolved by SDS-PAGE and
probed with anti-VP1, anti-VP2/VP3, and anti-GAPDH antibodies. Representative western blots are shown. E) DNA was extracted from BKPyV infected RPTE cells
treated with glibenclamide (20 μM) or cidofovir (15 mg/ml) and BKPyV genome replication was determined by qPCR analysis. Levels were normalised to untreated
controls. Fi) BKPyV infected RPTE cells were treated with glibenclamide (20 μM) or cidofovir (15 mg/ml) and the media fraction was harvested and used to infect
naïve RPTE cells. Fii) The percentage of BKPyV infected cells was quantified using IncuCyte ZOOM software and normalised to untreated cells. G) BKPyV infected
RPTE cells were treated with a range of concentrations of glibenclamide and concentration response curves were constructed. Data show mean values with SD
(n= 3); data in Fig. 1A were compared using Welch's test, Fig. 1B was analysed by 2-way ANOVA and a two-tailed unpaired t-test was used for the remaining figures
(*P < 0.05, **P < 0.005, ***P < 0.0005, ****P < 0.0001).
Fig. 2. Glibenclamide inhibits BKPyV independently of KATP channels. A) BKPyV infected RPTE cells were treated with glibenclamide (20 μM), tolbutamide
(150 μM), 5-HD (500 mM) and U-37883A (50 μM). At 48 hpi cells were fixed and stained for BKPyV VP1. Widefield images were captured using an IncuCyte ZOOM.
The percentage of BKPyV infected cells was quantified using IncuCyte ZOOM software and normalised to untreated cells (Open bars). Cell viability was assessed by
MTT assays. Values were normalised to untreated controls (grey bars). B) BK-VP1 expression is unaffected by SUR1 (ABCC8) and SUR2A/B (ABCC9a/b) silencing.
Cells were infected with BKPyV following the siRNA-mediated silencing of SUR1, SUR2A and SUR2B. Data are the mean ± SD normalised to scrambled RNA
controls. Data were compared using a 2-way ANOVA (*P < 0.05, **P < 0.005, ***P < 0.0005, ****P < 0.0001).
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transit, we made use of the observation that upon trafficking to the ER,
polyomaviruses interact with host chaperones to expose the previously
obscured VP2/VP3 minor capsid proteins (Hurdiss et al., 2016;
Goodwin et al., 2011; Nelson et al., 2013). Exposure of these minor
capsid proteins therefore serves as a surrogate marker to assess BKPyV
entry into the ER. To investigate the effects of CFTR inhibition on these
processes, RPTE cells were incubated with inhibitor compounds and
infected with virus for 10 h prior to fixation and immunostaining with
(caption on next page)
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anti-VP2/VP3 antibodies. In control cells, VP2/VP3 puncta were visible
in the perinuclear region of infected cells as would be expected as this
timepoint is too early for entry into the nucleus for virus replication
(Fig. 4Ci). In contrast, treatment of cells with either glibenclamide or
CFTR172 led to a reduction in the number of VP2/VP3 puncta (Fig. 4Ci-
ii). Glibenclamide and CFTR172 had no effects on the internalisation of
fluorescently labelled epidermal growth factor (EGF) (Fig. 4D), de-
monstrating that inhibitor treatment did not lead to a global inhibition
of kidney cell uptake pathways. The EGF assays were validated by the
inclusion of ammonium chloride (an inhibitor of endosomal acidifica-
tion) that as expected, had no influence on EGF uptake into cells but
would be predicted to inhibit post-entry EGFR trafficking. In contrast,
treatment with the dynamin inhibitor, Dynasore, significantly reduced
EGF internalisation. Finally we confirmed the post-entry effect of CFTR
inhibition on BKPyV since neither glibenclamide nor CFTR172 affected
the ability of BKPyV to bind to RPTECs (Fig. 4E). The culmination of
these data suggest that the blockade of CFTR specifically reduces
BKPyV trafficking to the ER, preventing the structural transitions ne-
cessary for exposure of the minor capsid proteins, explaining its in-
hibitory effects during the early stages of BKPyV infection.
3. Discussion
There is a pressing clinical need for therapeutics to control BKPyV
infection in immunosuppressed patients. Uncontrolled BKPyV replica-
tion is responsible for PVAN and uteric stenosis in kidney transplant
patients, and PVHC in haematopoietic stem cell transplant recipients. In
all these patients, high viraemia is associated with an increased risk of
disease progression. As such, understanding the BKPyV lifecycle is
critical to the development of anti- BKPyV therapeutics that can reduce
viral replication in immunosuppressed individuals, without the use of
current nephrotoxic, broad spectrum anti-viral agents such as cidofovir.
In this study, we demonstrate that the sulphonylurea drug glib-
enclamide inhibits BKPyV infection in primary RPTE cells. The drug is
most effective within the first 4 h of infection, indicating that it pri-
marily functions at a stage of the BKPyV lifecycle prior to nuclear entry
and viral transcription. Whilst considerable gaps in our understanding
of these early stages of the BKPyV lifecycle remain, it is known that
polyomaviruses take advantage of retrograde pathways and navigate
the endolysosomal system bound to their host ganglioside receptor
molecules (Nelson et al., 2013; Qian et al., 2009; Zhao and Imperiale,
2017). Endosome acidification activates a ganglioside-mediated sorting
process essential for trafficking its cargo into the ER (Qian et al., 2009).
Within the ER, interactions with cellular chaperones permit key con-
formational changes in the virus capsid that drive virus uncoating prior
to nuclear entry (Walczak et al., 2014). Thus, we postulated that the
cellular target for glibenclamide was a factor resident in the endosomal
system. The most likely targets of glibenclamide were the sulphony-
lurea (SUR) ABC-transporter proteins associated with the inward rec-
tifying K+ channels KIR 6.1 and 6.2, which form the well-characterised
KATP channels. However, a number of lines of evidence cast doubt on
this assumption. Firstly, neither the silencing of SUR1, SUR2A nor
SUR2B proteins influenced BKPyV infection (Aguilar-Bryan et al., 1995;
Inagaki et al., 1996). Moreover, the use of additional KATP channel in-
hibitor compounds failed to prevent BKPyV infection. KATP channels
were therefore discounted as the glibenclamide target.
CFTR is similarly sensitive to glibenclamide and is highly expressed
in the proximal tubules of the kidney. The inhibitory effects of the
CFTR-specific inhibitor CFTR172 were similar to those of glibenclamide,
suggesting an overlapping target. Depletion experiments using CFTR
siRNA were less efficacious at reducing VP1 expression; however, this is
likely due to the limited CFTR knockdown achieved due to the known
stability of the CFTR protein (half-life of over 48 h). Interestingly, the
level of reduction was similar to that observed in a recent whole
genome siRNA screen to identify host factors required for BKPyV in-
fection (Zhao and Imperiale, 2017) and we consistently observed an
increase in the levels of CFTR transcript in BKPyV infected cells. It is
plausible that the virus may actively drive CFTR expression if the host
factor is essential for the virus lifecycle. Alternatively, a redundant Cl-
transport channel in human kidney cells that is also targeted by both
CFTR172 and glibenclamide cannot be completely discounted.
A number of studies indicate a role for CFTR in endosome traf-
ficking and fusion (Bradbury, 1999). In particular, CFTR is enriched in
the apical endosomes of proximal tubule cells (Morales et al., 1996) and
co-localises with the vacuolar ATPase (v-ATPase), which is essential for
endosome acidification (Collaco et al., 2013). Given that a parallel Cl−
conductance into the interior-positive membrane potential created by
v-ATPase is essential for endosome acidification, it is possible that CFTR
regulates these processes in kidney cells (Carraro-Lacroix et al., 2010).
Whilst we have not yet addressed this directly, we did observe that
treatment with glibenclamide or CFTR172 significantly reduced the
transport of virions to the ER, a step that is blocked when endosome
acidification is impaired (Jiang et al., 2009; Qian et al., 2009).
Specific BKPyV genotypes are predictive of the clinical outcome of
infection (Pastrana et al., 2013; Solis et al., 2018; Korth et al., 2019). In
addition to BKPyV, other polyomaviruses cause disease in humans in-
cluding JC polyomavirus and Merkel cell polyomavirus, the former
causing PVAN in select cases (DeCaprio and Garcea, 2013). Since these
viruses also take advantage of retrograde trafficking, it is likely that
CFTR inhibitors will be similarly active against these pathogens. Two
other potential polyomaviruses (LIPyV and QPyV) have also been de-
tected in human specimens and their susceptibility to CFTR modulation
may further highlight a pan-family dependence (Gheit et al., 2017;
Ondov et al., 2019). Targeting host components has the distinct ad-
vantage of avoiding the evolution of virus escape mutants. Indeed, as
glibenclamide is currently in clinical use, our work suggests it may
represent a new and safe drug for the treatment of polyomavirus dis-
ease. A caveat is that glibenclamide must be administered to patients
prior to-, or early during infection (≤4 hpi). However, given the limited
side-effects of this compound, its administration to vulnerable patients
could prevent future BKPyV infections and/or reduce viral spread. As
such, the targeting of essential host channels such as CFTR may be a
promising avenue of research to treat BKPyV infection in im-
munosuppressed individuals.
Fig. 3. Pharmacological inhibition of CFTR impedes BKPyV infection. A) Cells were infected with BKPyV following the siRNA-mediated silencing of CFTR. Data
for Fig. 3A are the mean ± SD normalised to scrambled RNA controls. B) BKPyV infected RPTE cells were treated with increasing concentrations (0–10 μM) of
CFTR172. At 48 hpi, cells were fixed and stained for BKPyV VP1. The percentage of BKPyV infected cells was quantified using IncuCyte ZOOM software and
normalised to untreated cells (Open bars). Cell viability was assessed by MTT assays (grey bars). C) RPTE cells were infected with BKPyV at an MOI of 0.5 or 5 and
treated with 10 μM of CFTR172. The percentage of BKPyV infected cells was quantified using IncuCyte ZOOM software and normalised to untreated cells. D) RPTE
cells were treated with CFTR172 (10 μM) or glibenclamide (20 μM) for the first 10 h of BKPyV infection. Cells were then washed and the media was replaced with
growth media. Lysates were generated at 48 hpi and analysed by SDS PAGE. Samples were probed with anti-VP1 (ab597) and anti-VP2/VP3 (ab53983) antibodies.
GAPDH served as a loading control. E) DNA was extracted from BKPyV infected RPTE cells treated with CFTR172 or cidofovir and BKPyV genome replication was
determined by qPCR analysis. Expression levels were normalised to untreated controls. Fi) BKPyV infected RPTE cells were treated with CFTR172 (10 μM) or cidofovir
(15 mg/ml) and the media fraction was harvested and used to infect naïve RPTE cells. Fii) The percentage of BKPyV infected cells was quantified using IncuCyte
ZOOM software and normalised to untreated cells. G) BKPyV infected RPTE cells were treated with a range of concentrations of CFTR172 and concentration response
curves were constructed. Data are the mean ± SD; data were compared using a two-tailed unpaired t-test unless stated otherwise. Data for Fig. 3A were compared
using a 2-way ANOVA, Fig. 3B were compared using a 2-way ANOVA, (*P < 0.05, **P < 0.005, ***P < 0.0005, ****P < 0.0001).
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Fig. 4. Glibenclamide and CFTR172 inhibit an early post-entry stage of BKPyV infection. A-B) RPTE cells were treated with glibenclamide (20 mM) or CFTR172
(10 mM) at the time points indicated during a synchronous BKPyV infection. Cells were fixed and probed with anti-VP1 and anti-mouse Alexa-fluor 488 secondary
antibodies. The percentage of BKPyV infected cells was quantified using IncuCyte ZOOM software and normalised to untreated cells. Ci) RPTE cells were treated with
CFTR172 (10 μM) or glibenclamide (20 μM) and infected with BKPyV at an MOI of 3 for 10 h prior to fixing and staining for VP2/VP3 (green). Nuclei were stained
with DAPI (blue). Cii) Quantification of the images from N = 3 samples. Values were normalised to untreated controls. D) RPTE cells were pre-treated with CFTR172
(10 μM), glibenclamide (20 μM) ammonium chloride (6 mM) and the dynamin inhibitor dynasore (10 μM) and pulsed with Alexa fluor-488 conjugated EGF for
45 min. Cells were fixed and the number of EGF-positive fluorescent puncta were measured using IncuCyte ZOOM software. Data are the mean ± SD; data in Fig. 4A
and 4B were compared using Welch's test, and the remaining data were compared using a two-tailed unpaired t-test (*P < 0.05, **P < 0.005, ***P < 0.0005,
****P < 0.0001). (E) Purified BKPyV was labelled using the Molecular Probes Alexa Fluor® 488 Protein Labelling Kit (Invitrogen™). RPTE cells were treated with
inhibitors for 24 h and cells were re-suspended in ice-cold Opti-MEM. Cells were chilled at 4 °C for 15 min prior to addition of Alexa Fluor 488-labelled BKPyV
(AF488-BKPyV) diluted in Opti-MEM at MOI 0.5. The mixture was chilled at 4 °C for 1 h and unbound virus was removed through two PBS washes. Cells were fixed
with 4% paraformaldehyde and virus-binding to cells was assessed using the CytoFLEX S Flow Cytometer (N = 3).
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4. Experimental procedures
4.1. Cell culture
RPTE cells (Lonza) were maintained in Renal Epithelial Cell Growth
Medium 2 with supplements (ready-to-use) (PromoCell) at 37 °C in a
5% CO2 humidified incubator. Cells were maintained up to passage 7
(Panou et al., 2018).
4.2. BKPyV infections
RPTE cells seeded into 6-well dishes (2 x 105 cell/ml) were chilled
at 4 °C for 15 min and infected with BKPyV (Dunlop) stocks at the
indicated MOIs in serum free media (Opti-MEM) at 4 °C. After 2 h, cells
were incubated at 37 °C to allow virus infection to proceed.
4.3. Ion channel modulators
Stock solutions of TEA, BaCl2, 4-AP, 5-HD and U-373883A (Sigma
Aldrich) were produced in dH2O. Quinidine, glibenclamide, tolbuta-
mide, VU-591, Dynasore (dynamin inhibitor) and CFTR172 were pro-
duced in DMSO.
4.4. Virus drug assays
RPTE cells (2 x 103 cells per well) in 96-well plates were chilled at
4 °C for 15 min and infected with BKPyV in Opti-MEM (MOI 0.5) for
2 h at 4 °C. Cells were then washed to remove unbound virus and
treated with the indicated ion channel compounds. After 48 h, cells
were fixed, stained and processed for IncuCyte ZOOM analysis.
4.5. Time of addition experiments
RPTE cells (2 x 10 3 cells per well) in 96-well plates were chilled at
4 °C for 15 min and infected with BKPyV in Opti-MEM (MOI 0.5) for
2 h at 4 °C. Virus was then removed, cells were washed in PBS, and
treated with the indicated compounds at 0, 1, 2, 4, 6, 8 and 10 hpi. Cells
were incubated for a total of 48 h. Cells were then fixed, stained and
analysed by IncuCyte ZOOM analysis.
4.6. siRNA transfections
RPTE cells were transfected with 50 nM of pooled siRNA using li-
pofectamine 2000 (1:2 ratio). After 48 h, cells were infected with
BKPyV (MOI of 0.5) for 2 h at 37 °C. Virus was then removed and cells
were incubated in fresh media for a further 48 h prior to analysis.
4.7. Preparation of protein lysates
RPTE cells were lysed in E1A lysis buffer (50 mM HEPES pH 7.0,
250 mM NaCl, 0.1% NP-40, 1 mM EDTA, 1 mM DTT and 1 x Protease
inhibitor cocktail EDTA-free (Jiang et al., 2009). Lysates were sonicated
3 times, incubated on ice for 1 h, and centrifuged at 13,000 rpm for
5 min.
4.8. Western blotting
Proteins were resolved by 10% SDS PAGE and transferred onto
HyBondTM-C Extra mixed ester nitrocellulose membranes (Amersham
Biosciences) using a semi-dry Turbo-Blotter (BioRad). Membranes were
probed with primary antibodies against BKPyV VP1 (PAb597: 1:250) an
anti-SV40-VP1 antibody, GAPDH (Santa Cruz sc-47724: 1:5000) and
BKPyV VP2/VP3 (Abcam ab53983: 1:1000) overnight at 4 °C as pre-
viously described (Panou et al., 2018).
4.9. Quantitative real-time PCR
Total RNA was extracted using the E.Z.N.A. Total RNA Kit I (Omega
Bio- Tek) according to the manufacturer's protocol. RNA (1 μg) was
DNase treated using RQ1 RNase-Free DNase (Promega) and reverse
transcribed with a mixture of random and oligo (dT) primers using
qScriptTM cDNA SuperMix kit (Bio-Rad LaboratoriesRT-qPCRs were
performed using the QuantiFast SYBR Green PCR kit (Qiagen). Data
were analysed using the ΔΔCt method on Rotor-Gene 6000 software
(Panou et al., 2018). Values were normalised to U6). Primer pairs were
as follows: VP1 F 5′ CCA GAT GAA AAC CTT AGG GGC TT 3′, VP1 R 5′
AGA TTT CCA CAG GTT AGG TCC TCA TT 3′, U6 F 5′ CTC GCT TCG
GCA CA 3′, U6 R 5′ AAC GCT TCA CGA ATT TGC GT 3′, CFTR F1 5′ TGG
ATC GCT CCT TTG CAA GT 3′, CFTR R1 5′ AAG TCC ACA GAA GGC
AGA CG 3′, CFTR F2 5′ AGG AAC GCT CTA TCG 3′, CFTR R2 5′ TGA
CAG CTT TAA AGT CTT 3'.
4.10. IncuCyte Zoom analysis
RPTE cells were cultured in 96-well plates at a density of 2 x
103 cells/ml for 16 h prior to infection with BKPyV. Virus was then
removed and cells were incubated for a further 48 h. Infected cells were
then washed in PBS for 5 min and fixed in 4% paraformaldehyde for
10 min at room temperature. Cells were permeabilised in 0.1% Triton-
X100 in PBS (v/v) for 15 min and blocked in 1% BSA in PBS (Sigma
Aldrich) for 30 min at room temperature. Cells were then probed with
primary anti-VP1 (PAb597) (1:250) antibodies overnight at 4 °C and
labelled with secondary anti-mouse Alexa Fluor 488-conjugated anti-
bodies (1:250) (Thermo Fisher Scientific) for 2 h at room temperature.
Cells were washed and imaged using the IncuCyte Dual colour ZOOM
FLR system (Essen Bioscience). Images were collected with single scans
and fluorescent object counts per well were analysed using ZOOM
software (Stewart et al., 2015).
4.11. Cell viability assays
RPTE cells in 96-wells were treated with inhibitor compounds for up
to 48 h. MTT reagent (1 mg/ml) was added in serum-free media and
cells were incubated at 37 °C in the dark for 30 min. MTT solution was
then replaced with 100 μl DMSO for 5 min, and optical densities were
read at 570 nm on a microplate reader.
4.12. Immunofluorescence staining
RPTE cells on glass coverslips were BKPyV infected for 2 h and drug
treated. Cells were maintained at 37 °C in a 5% CO2 humidified in-
cubator for a further 10 h. Cells were washed in PBS, fixed with 4%
paraformaldehyde and permeabilised in 0.1% Triton-X100 in PBS. Cells
were then blocked in 1% BSA in PBS for 30 min at room temperature
and labelled with anti-VP2/VP3 (ab53983) (1:500) antibodies over-
night at 4 °C. Cells were then washed and labelled with secondary anti-
rabbit Alexa Fluor 488-conjugated antibodies (1:1000) (Thermo Fisher
Scientific) for 2 h at room temperature. Coverslips were mounted with
DAPI-containing ProLong Gold antifade reagent. Immunofluorescence
analysis was performed on a LSM 880 Zeiss confocal microscope.
Images were analysed for a number of pixels using Zeiss bioimaging
software.
4.13. EGF uptake assays
RPTE cells in 12-well plates were treated with the indicated drugs
for 30 min and pulsed with 2 μg/ml Alexa Fluor® 488 EGF in Opti-MEM.
Cells were incubated at 37 °C for a further 20 min and fixed in 4%
paraformaldehyde. EGF uptake was assessed on an IncuCyte Dual
colour ZOOM FLR (Essen Bioscience). Images were collected with single
scans and analysed using ZOOM software (fluorescent object counts per
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well).
4.14. Virion binding assays
Purified BKPyV was labelled using the Molecular Probes Alexa
Fluor® 488 Protein Labelling Kit (Invitrogen™) according to the man-
ufacturers protocols. RPTE cells were treated with inhibitors for 24 h
prior to detachment, and cells were re-suspended in ice-cold Opti-MEM.
Cells were chilled at 4 °C for 15 min prior to addition of Alexa Fluor
488-labelled BKPyV (AF488-BKPyV) diluted in Opti-MEM at MOI 0.5.
The mixture was chilled at 4 °C for 1 h and unbound virus was removed
through 2 x PBS washes. Cells were fixed with 4% paraformaldehyde
and virus-binding was assessed using the CytoFLEX S Flow Cytometer
(Beckman Coulter).
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